Android app on Google Play

Jefferies Starts Dyax Corp. (DYAX) at Buy

March 5, 2013 7:00 AM EST Send to a Friend
Get Alerts DYAX Hot Sheet
Price: $6.73 -1.03%

Rating Summary:
    5 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 9 | New: 22
Trade DYAX Now!
Join SI Premium – FREE
Jefferies initiates coverage on Dyax Corp. (NASDAQ: DYAX) with a Buy. PT $6.00.

The firm comments, "With its wholly owned marketed orphan drug asset and a widely partnered tech platform, DYAX is an attractive small-cap biotech play. While long-term U.S. Kalbitor sales grow steadily, royalties from potential Japan Kalbitor sales and U.S. ramucirumab sales across an increasing number of cancer indications provide additional legs of growth near/mid-term, likely driving significant value not factored into the current share price."

For an analyst ratings summary and ratings history on Dyax Corp. click here. For more ratings news on Dyax Corp. click here.

Shares of Dyax Corp. closed at $3.27 yesterday.




You May Also Be Interested In


Related Categories

Hot New Coverage, New Coverage

Related Entities

Jefferies & Co

Add Your Comment